Financing - May 18, 2026
British AI pioneer Isomorphic Labs secures USD 2.1 billion
The Series B funding will be used to power the company's AI drug design engine, scale its business globally and progress its drug candidate pipeline.
Financing - May 4, 2026
Moleculent raises USD 20 million
The financing round was led by Rubicon Healthcare Partners, with participation from ARCH Venture Partners, Eir Ventures, and other existing investors.
Financing - April 28, 2026
Ray Therapeutics raises USD 125 million, Novo Holdings doubles down on optogenetic eye gene therapy
The US company has closed an upsized, oversubscribed Series B to advance its optogenetic gene therapy pipeline for blinding retinal diseases with Novo Holdings reinforcing a strong Nordic investment footprint in late‑stage ophthalmology.
Financing - April 24, 2026
Elicera carries out a rights issue of approx SEK 73 million
Elicera Therapeutics has resolved to carry out a rights issue of shares of approximately SEK 72.8 million with preferential rights for the company’s existing shareholders.
Financing - March 19, 2026
Everdrone raises SEK 36 million
The recently completed funding round was led by the investment firm Sciety.
Financing - March 3, 2026
SynAct Pharma has carried out a directed issue of new shares
Through the directed issue, the company will receive approximately SEK 51.9 million.
